Allogene Therapeutics Inc (NAS:ALLO)
$ 2.99 -0.01 (-0.33%) Market Cap: 625.25 Mil Enterprise Value: 269.70 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 34/100

Allogene Therapeutics Inc Business Update Call Transcript

Jan 10, 2022 / 04:30PM GMT
Release Date Price: $12.2 (-9.36%)
Operator

Hello. Thank you for standing by for this conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to turn the conference over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, you may begin.

Christine Cassiano
Allogene Therapeutics, Inc. - Chief Communications Officer

Thank you, operator, and thanks to all of you for joining our call this morning. Before market open, Allogene issued a press release announcing that the FDA has removed the clinical hold on all of our AlloCAR T clinical trials. This press release as well as today's webcast are available on our website. Here with us to discuss today's news will be Dr. David Chang, our President and Chief Executive Officer; and Dr. Rafael Amado, Executive Vice President of Research and Development; and Chief Medical Officer.

During the Q&A, they will be joined by Dr. Eric Schmidt, Chief Financial Officer. (Operator Instructions) During today's call, we will be making certain forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot